| Literature DB >> 35202125 |
Asmaa Sadat1, Radwa Reda Shata2, Alshimaa M M Farag3, Hazem Ramadan4, Adel Alkhedaide5, Mohamed Mohamed Soliman5, Mohamed Elbadawy6, Amira Abugomaa7, Amal Awad1.
Abstract
The present study aimed to investigate the prevalence, antibiotic susceptibility profiles, and some toxin genes of Panton-Valentine leukocidin (PVL)-positive Staphylococcus aureus (S. aureus) in unpasteurized raw cow's milk collected from retail outlets located at Mansoura, Dakahliya governorate, Egypt. In that context, a total of 700 raw cow's milk samples were investigated for the presence of S. aureus, which was identified in 41.1% (288/700) of the samples. Among the S. aureus isolates, 113 PVL-positive S. aureus were identified and subjected for further analysis. The PVL-positive S. aureus were investigated for the existence of toxin-related genes, including hemolysin (hla), toxic shock syndrome toxin-1 (tst), and enterotoxins (sea, seb, sec, see, seg, sei, and selj). Genotypic resistance of PVL-positive strains was performed for the detection of blaZ and mecA genes. Among the PVL-positive S. aureus, sea, seb, and sec were detected in 44.2, 6.2%, and 0.9%, respectively, while the hla and tst genes were identified in 54.9% and 0.9%, respectively. The blaZ and mecA genes were successfully identified in 84.9 (96/113) and 32.7% (37/113) of the total evaluated S. aureus isolates, respectively. PVL-positive S. aureus displayed a high level of resistance to penicillin, ampicillin, and trimethoprim-sulfamethoxazole. Multidrug resistance (resistant to ≥3 antimicrobial classes) was displayed by all methicillin-resistant S. aureus (MRSA) and 38.2% of methicillin-sensitive S. aureus (MSSA) isolates. The obtained findings are raising the alarm of virulent PVL-positive MRSA clones in retail milk in Egypt, suggesting the requirement for limiting the use of β-lactam drugs in food-producing animals and the importance of implementing strong hygiene procedures in dairy farms and processing plants.Entities:
Keywords: MRSA; Staphylococcus aureus; antimicrobial resistance; enterotoxins; pvl gene
Mesh:
Substances:
Year: 2022 PMID: 35202125 PMCID: PMC8876356 DOI: 10.3390/toxins14020097
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Prevalence of PVL-positive Staphylococcus aureus, methicillin-resistant (MRSA), and methicillin-sensitive Staphylococcus aureus (MSSA) strains.
Frequency distribution of antimicrobial resistance and virulence genes among the examined PVL-positive Staphylococcus aureus.
| Gene | Frequency Distribution | ||
|---|---|---|---|
| PVL-Positive MRSA ( | PVL-Positive MSSA ( | Total PVL-Positive | |
|
| 37 (32.7%) | 0 | 37 (32.7%) |
|
| 32 (28.3%) | 64 (56.6%) | 96 (84.9%) |
|
| 0 | 1 (0.9%) | 1 (0.9%) |
|
| 18 (15.9%) | 44 (38.9%) | 62 (54.9%) |
|
| 20 (17.7%) | 30 (26.6%) | 50 (44.2%) |
|
| 2 (1.8%) | 5 (4.4%) | 7 (6.2%) |
|
| 0 | 1 (0.9%) | 1 (0.9%) |
|
| 0 | 0 | 0 |
|
| 0 | 0 | 0 |
|
| 0 | 0 | 0 |
|
| 0 | 0 | 0 |
|
| 0 | 1 (0.9%) | 1 (0.9%) |
Antimicrobial susceptibility of PVL-positive Staphylococcus aureus strains.
| Antimicrobial Agent | Family | CPD | PVL-Positive MRSA ( | PVL-Positive MSSA ( | PVL-Positive | |||
|---|---|---|---|---|---|---|---|---|
| Resistant | Sensitive | Resistant | Sensitive | Resistant | Sensitive | |||
| Penicillin (P) | β-lactam | 10 μg | 37 (32.7%) | 0 | 65 (57.5%) | 11 (9.7%) | 102 (90.3%) | 11 (9.7%) |
| Ampicillin(AMP) | β-lactam | 10 μg | 37 (32.7%) | 0 | 43 (38.05%) | 33 (29.2%) | 80 (70.8%) | 33 (29.2%) |
| Ciprofloxacin (CIP) | Fluoroquinolone | 5 μg | 24 (21.2%) | 13 (11.5%) | 23 (20.4%) | 53 (46.9%) | 47 (41.6%) | 66 (58.4%) |
| Chloramphenicol (C) | Phenicols | 30 μg | 12 (10.6%) | 25 (22.1%) | 4 (3.5%) | 72 (63.7%) | 16 (14.0%) | 97 (85.8%) |
| Clindamycin (DA) | Lincosamide | 2 μg | 20 (17.7%) | 17 (15.04%) | 22 (19.5%) | 54 (47.8%) | 42 (37.2%) | 71 (62.8%) |
| Erythromycin (E) | Macrolide | 15 μg | 22 (19.5%) | 15 (13.3%) | 17 (15.04%) | 59 (52.2%) | 39 (34.5%) | 74 (65.5%) |
| Gentamicin (CN) | Aminoglycoside | 10 μg | 11 (9.7%) | 26 (23%) | 12 (10.6%) | 64 (56.6%) | 23 (20.4%) | 90 (79.6%) |
| Tetracycline (TE) | Tetracycline | 30 μg | 32 (28.3%) | 5 (4.4%) | 22 (19.5%) | 54 (36.3%) | 54 (47.79%) | 59 (40.7%) |
| Trimethoprim- sulfamethoxazole (SXT) | Sulphonamide | 25 μg | 35 (31.0%) | 2 (1.77%) | 27 (23.9%) | 49 (43.6%) | 62 (54.9%) | 51 (45.13%) |
No: number.
Antimicrobial resistance patterns and antibiotypes of PVL-positive MRSA strains.
| Antibiotypes | Resistance Pattern | Isolate No (%) ( | MAR Index | MAR |
|---|---|---|---|---|
| I | P, AMP, C, and TE | 1 (2.7%) | 0.44 | + |
| II | P, AMP, SXT, and TE | 1 (2.7%) | 0.44 | + |
| III | P, AMP, CIP, and CN | 1 (2.7%) | 0.44 | + |
| IV | P, AMP, C, SXT, and TE | 4 (10.8%) | 0.56 | + |
| V | P, AMP, DA, E, and SXT | 1 (2.7%) | 0.56 | + |
| VI | P, AMP, CIP, SXT, and TE | 5 (13.5%) | 0.56 | + |
| VII | P, AMP, C, DA, SXT, and TE | 1 (2.7%) | 0.67 | + |
| VIII | P, AMP, CIP, C, SXT, and TE | 1 (2.7%) | 0.67 | + |
| IX | P, AMP, DA, E, SXT, and TE | 2 (5.4%) | 0.67 | + |
| X | P, AMP, E, CN, SXT, and TE | 1 (2.7%) | 0.67 | + |
| XI | P, AMP, CIP, DA, SXT, and TE | 1 (2.7%) | 0.67 | + |
| XII | P, AMP, CIP, DA, E, SXT, and TE | 7 (18.9%) | 0.78 | + |
| XIII | P, AMP, C, DA, E, SXT, and TE | 1 (2.7%) | 0.78 | + |
| XIV | P, AMP, CIP, E, CN, SXT, and TE | 1 (2.7%) | 0.78 | + |
| XV | P, AMP, CIP, DA, E, CN, and SXT | 3 (8.1%) | 0.78 | + |
| XVI | P, AMP, DA, E, CN, SXT, and TE | 1 (2.7%) | 0.78 | + |
| XVII | P, AMP, CIP, C, E, SXT, and TE | 1 (2.7%) | 0.89 | + |
| XVIII | P, AMP, CIP, C, E, CN, SXT, and TE | 1 (5.4%) | 0.89 | + |
| XIX | P, AMP, CIP, DA, E, CN, SXT, and TE | 1 (2.7%) | 0.89 | + |
| XX | P, AMP, CIP, C, DA, E, CN, SXT, and TE | 2 (5.4%) | 1 | + |
Antimicrobial resistance patterns and antibiotypes of PVL-positive MSSA strains.
| Antibiotypes | Resistance Pattern | Isolate No (%) | MAR Index | MAR |
|---|---|---|---|---|
| I | 0 | 5 (6.58%) | 0.00 | - |
| II | P | 26 (34.2%) | 0.11 | - |
| III | CIP | 1 (1.3%) | 0.11 | - |
| IV | AMP | 3 (3.9%) | 0.11 | - |
| V | P and AMP | 6 (7.9%) | 0.22 | - |
| VI | P and DA | 1 (1.3%) | 0.22 | - |
| VII | AMP and DA | 2 (2.6%) | 0.22 | - |
| VIII | P, AMP, and SXT | 1 (1.3%) | 0.33 | - |
| IX | P, AMP, and CIP | 2 (2.6%) | 0.33 | - |
| X | P, AMP, CIP, and DA | 2 (2.6%) | 0.44 | + |
| XI | P, AMP, SXT, and TE | 4 (5.2%) | 0.44 | + |
| XII | P, AMP, C, TE, and CIP | 1 (1.3%) | 0.56 | + |
| XIII | P, AMP, CIP, CN, and SXT | 1 (1.3%) | 0.56 | + |
| XIV | P, AMP, CIP, SXT, and TE | 1 (1.3%) | 0.56 | + |
| XV | P, AMP, E, SXT, and TE | 1 (1.3%) | 0.56 | + |
| XVI | P, AMP, CIP, C, and SXT | 1 (1.3%) | 0.56 | + |
| XVII | P, AMP, CN, E, SXT, and TE | 1 (1.3%) | 0.67 | + |
| XVIII | P, AMP, CIP, DA, E, and SXT | 3 (3.9%) | 0.67 | + |
| XIX | P, AMP, CN, DA, SXT, and TE | 2 (2.6%) | 0.67 | + |
| XX | P, AMP, CIP, DA, E, SXT, and TE | 2 (2.6%) | 0.78 | + |
| XXI | P, AMP, DA, E, CN, SXT, and TE | 1 (1.3%) | 0.78 | + |
| XXII | P, AMP, CIP, C, DA, E, SXT, and TE | 2 (2.6%) | 0.89 | + |
| XXIII | P, AMP, CIP, DA, E, CN, SXT, and TE | 7 (9.1%) | 0.89 | + |
Figure 2Association of resistance phenotypes, resistance genes, and virulence-associated genes in PVL-positive Staphylococcus aureus. The blue and orange colors of the boxes indicate positive and negative correlations, respectively. The strength of the colors corresponds to the numerical value of the correlation coefficient (r).
Sequences of primers and PCR conditions for the targeted genes examined in the present study.
| Target Gene | Primer Direction and Sequence | Amplicon Size (bp) | Reference |
|---|---|---|---|
|
| F: GTGCTGGCATATGTATGGCAATTG | 660 | [ |
| R: CTGAATCAGCGTTGTCTTCGCTCCAA | |||
|
| F: ATCATTAGGTAAAATGTCTGGACA | 433 | [ |
| R: GCATCAACTGTATTGGATAGCAAAAGC | |||
|
| F: TCCAGATTACAACTTCACCAGG | 162 | [ |
| R: CCACTTCATATCTTGTAACG | |||
|
| F: TACAACTGTAATATCGGAGGG | 861 | [ |
| R: CATTACACTCTTGGCGGTTTC | |||
|
| F: CGTAAGCCCTTTGTTGCTTG | 543 | [ |
| R: CCACCCGTTTTATCGCTTGAAC | |||
|
| F: CCGGTACTACAGATATTGGAAGC | 744 | [ |
| R: GGTAATCATCACGAACTCGTTCG | |||
|
| F: TCG CAT CAA ACT GAC AAA CG | 478 | [ |
| R: GCA GGT ACT CTA TAA GTG CC | |||
|
| F: GCA GGG AAC AGC TTT AGG C | 520 | [ |
| R: GTT CTG TAG AAG TAT GAA ACA CG | |||
|
| F: CTT GTA TGT ATG GAG GAA TAA CAA | 283 | [ |
| R: TGC AGG CAT CAT ATC ATA CCA | |||
|
| F: TAC CAA TTA ACT TGT GGA TAG AC | 170 | [ |
| R: CTC TTT GCA CCT TAC CGC | |||
|
| F: CGT CTC CAC CTG TTG AAG G | 327 | [ |
| R: CCA AGT GAT TGT CTA TTG TCG | |||
|
| F: CAA CTC GAA TTT TCA ACA GGT AC | 465 | [ |
| R: CAG GCA GTC CAT CTC CTG | |||
|
| F: CAT CAG AAC TGT TGT TCC GCT AG | 142 | [ |
| R: CTG AAT TTT ACC ATC AAA GGT AC |